Immunic Inc. Stock Crashes 57% as Top-Line Data of Oral DHODH Inhibitor Misses
(Immunic) Shares of Immunic, Inc. fell 57% on Thursday after top-line data for its phase 2 CALDOSE-1 trial of lead asset, vidofludimus calcium, failed to achieve primary endpoint. The company…